Home / Stock ratings / BAX
Stock rating · Surgical & Medical Instruments & Apparatus
Baxter International Inc. (BAX) Stock Rating & Analysis
As of October 13, 2026, MELANY rates Baxter International Inc. 75 out of 100 (Highest Conviction). Its highest factor score is catalyst setup at 97, and its lowest is business quality at 35.
MELANY ratingRated 2026-10-13BAX · composite score
About Baxter International Inc.
Baxter supplies a range of medical products and equipment to providers. Its legacy operations sell injectable therapies for care settings, including IV pumps, administrative sets, and solutions, plus nutritional products and surgical sealants and hemostatic agents. Its late-2021 Hillrom acquisition added hospital beds, operating room equipment, and patient monitoring tools. Baxter sold its kidney care tools in early 2025.
Rating as of 2026-10-13 · this is a dated snapshot; the live rating is in the app (Pro, free for 30 days). The price above updates in real time.
Why BAX scores 75/100
BAX's 8 factor scores run from 35 to 97, and 2 of them sit above its composite of 75. Here is how BAX breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- FCF yield 7.8%
Margins, returns on capital, and balance-sheet strength.
Direction and relative strength of the recent share-price trend.
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 3 of last 4 quarters
- Avg EPS beat +16%
- Earnings in 16 days (strong beat history)
What Wall Street price targets and revisions are signalling.
- Institutional net buying +4.5%
Near-term events that could move the stock.
- Earnings in 16 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How BAX compares
As of October 13, 2026, Baxter International Inc. ranks 1st of the 8 companies with a MELANY rating page in its SEC industry group (Surgical & Medical Instruments & Apparatus), where the average score is 68.
Key risks for BAX
- No positive trailing earnings, valuation cannot be anchored to current P/E
Sector and theme context
Baxter International Inc. sits in the Healthcare sector theme, which MELANY currently rates 59/100 for strength. Theme strength feeds BAX's momentum and catalyst factors above.
BAX trade plan (Pro)
MELANY has a full position plan for Baxter International Inc.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.
How MELANY rates BAX
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Baxter International Inc.'s 75/100 reflects speculative factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about BAX
Is Baxter International Inc. (BAX) a buy?
As of 2026-10-13, MELANY rated Baxter International Inc. Highest Conviction with a composite score of 75/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Baxter International Inc.'s MELANY score?
Baxter International Inc. (BAX) has a MELANY composite score of 75/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the BAX stock rating calculated?
MELANY scores BAX from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Baxter International Inc. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Baxter International Inc. (BAX) Highest Conviction with a composite of 75/100 as of 2026-10-13. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the BAX stock price forecast?
MELANY does not publish price targets or forecasts for BAX. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 75/100 across eight factors for Baxter International Inc., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is BAX stock overvalued or undervalued?
MELANY's valuation factor currently reads 70/100 for Baxter International Inc., where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives BAX's read.
What price should I buy BAX at?
Rather than chasing the current price, MELANY computes a smart entry zone for BAX: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.
What are the risks of buying BAX stock?
The top risks MELANY currently flags for Baxter International Inc.: No positive trailing earnings, valuation cannot be anchored to current P/E. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Baxter International Inc. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 35/100 for Baxter International Inc., and earnings track record, at 88/100. The 75/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will BAX stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 75/100 for BAX right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this BAX rating?
The rating on this page is a snapshot of MELANY's read as of 2026-10-13. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores BAX continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, BAX included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.